Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 24Breast 8Gastrointestinal 7Thoracic 4Genitourinary 4Head & Neck 3Sarcoma 1Other solid neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 10Lymphoma 7Lymphoma, Follicular 5Lymphoma, Non-Hodgkin 4Lymphoma, T-Cell, Cutaneous 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Melanoma 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Testicular Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1

Interventions

pembrolizumab 6Paclitaxel 4Cyclophosphamide 4Psychiatric Rehabilitation 3Flow Cytometry 3Filgrastim 3Drug Therapy 3Carboplatin 3valspodar 2trametinib 2sargramostim 2epacadostat 2dabrafenib 2X-Rays 2Specimen Handling 2Nivolumab 2Microarray Analysis 2Methylprednisolone 2Melphalan 2Injections 2Immunologic Techniques 2Gemcitabine 2Dexamethasone 2Dasatinib 2Biopsy 2Azacitidine 2Analgesia 2Amifostine 2Alemtuzumab 2vocimagene amiretrorepvec 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × durvalumab × Lymphoid × Clear all
NCT03323398 2024-07-31

Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies

ModernaTX, Inc.

Phase 1/2 Terminated
79 enrolled 18 charts
GynecologicLymphoid

Lymphoma, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡